Zoe Quandt

Zoe Quandt, MD MS, is an endocrinologist and physician scientist at the University of California San Francisco (UCSF) School of Medicine. She serves as the leader of the UCSF Metabolic and Endocrine Cancer Immunotherapy Toxicity (MEND-IT) Clinic, focusing on the intersection of endocrinology and oncology. Her clinical and research work centers on understanding and managing endocrine side effects of cancer treatments, particularly immune-related adverse events from cancer immunotherapy.

Dr. Quandt's educational background includes:

• BA in Biology from Brown University
• Residency in Internal Medicine at Stanford Hospital and Clinics
• MS in Health and Medical Sciences from UC Berkeley
• Fellowship in Endocrinology and Diabetes at UCSF
• MD from UCSF Medical School

Dr. Quandt's primary research interests focus on the endocrine complications of cancer immunotherapy. She investigates immune-related adverse events, particularly those affecting metabolic and endocrine systems, including autoimmune diabetes, adrenal insufficiency, and thyroid disorders that occur as side effects of immune checkpoint inhibitors. Her work bridges clinical care with translational research to better understand the mechanisms, risk factors, and management strategies for these complications. She employs approaches ranging from clinical cohort studies to genetic and immunological analyses to identify predictors of toxicity and improve patient outcomes during cancer treatment.

Analysis of Dr. Quandt's recent publications reveals a strong focus on immune-related adverse events from cancer immunotherapy, particularly endocrine complications. Her work spans multiple cancer types including melanoma, breast cancer, and lung cancer. Methodologically, she combines clinical epidemiology with translational approaches including genetic analysis (polygenic risk scores, HLA associations), immunological studies, and innovative applications of artificial intelligence for adverse event detection. Her research demonstrates growing interest in predictive models for toxicity risk and personalized approaches to managing immunotherapy complications.

Dr. Quandt has been involved in significant collaborative research efforts, including the I-SPY2 trial and multi-institutional studies on immune toxicity. Her work has contributed to understanding the timing, risk factors, and mechanisms of endocrine complications from immunotherapy. While specific awards are not mentioned in the available information, her leadership of the MEND-IT Clinic and numerous high-impact publications demonstrate recognition of her expertise in this specialized field.